PBLS on Nasdaq

Parabilis Medicines, Inc.

Parabilis Medicines, Inc. is an American pharmaceutical preparations company based in Cambridge.¹ Its shares trade on Nasdaq under the symbol PBLS.¹

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

TickerPBLS on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersCambridge, Massachusetts¹
Incorporated inDE²
Business address30 Acorn Park Drive, 6Th Floor, Cambridge, Ma 02140²
Filer category, Emerging growth company²
Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Parabilis Medicines, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Parabilis Medicines, Inc.

ARCH Venture Fund XII, L.P. Filed SCHEDULE 13G on Parabilis Medicines, Inc., latest Aug 14, 2026
FMR LLC Filed SCHEDULE 13G on Parabilis Medicines, Inc., latest Aug 6, 2026
RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13D on Parabilis Medicines, Inc., latest Jun 18, 2026

Parabilis Medicines, Inc. Cambridge, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Parabilis Medicines, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive officerMathai Mammen Jun 9, 2026 to now³
PresidentMathai Mammen Jun 9, 2026 to now³
Chief financial officerThomas Rodolpho Kotarakos Jun 9, 2026 to now⁴

Board members and other officers (14)

OfficerHelen Huei-In Ho Jun 9, 2026 to now⁵
Chief Medical OfficerMohammed Fawzi Benzaghou Jun 9, 2026 to now⁶
OfficerRohin Mhatre Jun 9, 2026 to now⁷
Board memberAlan Sebulsky Jun 9, 2026 to now⁸
Board memberAlexis Borisy Jun 9, 2026 to now⁹
Board memberBarbara Weber Jun 9, 2026 to now¹⁰
Board memberEdward M. Fitzgerald Jun 9, 2026 to now¹¹
Board memberJake Simson Jun 9, 2026 to now¹²
Board memberKrishna Yeshwant Jun 9, 2026 to now¹³
Board memberMathai Mammen Jun 9, 2026 to now³
Board memberPeter Kolchinsky Jun 9, 2026 to now¹⁴
Board memberRajeev M. Shah Jun 9, 2026 to now¹⁴
Board memberCraig Tendler Aug 25, 2026 to now¹⁵
General counselTeresa Jurgensen Jun 9, 2026 to now¹⁶

Named in SEC Form D filings

People the company listed in its private-offering notices.

Executive Officer, DirectorGregory L. Verdine named Dec 2, 2022¹⁷
Executive OfficerWeiQing M. Zhou named Dec 2, 2022¹⁷
DirectorCorey S. Goodman named Dec 2, 2022¹⁷
DirectorJeffrey A. Leerink named Dec 2, 2022¹⁷
DirectorRick M. Klausner named Dec 2, 2022¹⁷

Former names

FOG PHARMACEUTICALS, INC.Nov 13, 2015 to Dec 2, 2022²

Timeline

Sep 15, 20268-K Regulation FD disclosure¹⁸
Sep 2, 20268-K Executive or director change¹⁹
Aug 25, 20268-K Executive or director change; Regulation FD disclosure²⁰
Aug 13, 20268-K Results of operations; Regulation FD disclosure²¹
Jun 11, 20268-K Entered a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed²²
Jun 9, 2026New chief executive Mathai Mammen becomes CEO³

Calendar

Coming up

Nov 12, 2026Reports results for the quarter ending Sep/2026²³

When it reported results

Aug 13, 2026Reported quarterly or annual results²¹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

56 filings to the SEC since October 2021: 1 quarterly reports, 5 major events, 34 insider forms, 3 large holders, 1 private raises, 12 other. The latest 20:

Sep 15, 20268-K EDGAR
Sep 2, 20268-K EDGAR
Aug 25, 20264 EDGAR
Aug 25, 20263 EDGAR
Aug 25, 20268-K EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 13, 202610-Q EDGAR
Aug 13, 20268-K EDGAR
Aug 6, 2026SCHEDULE 13G EDGAR
Jul 22, 20264 EDGAR
Jun 29, 20264 EDGAR
Jun 29, 20263 EDGAR
Jun 18, 2026SCHEDULE 13D EDGAR
Jun 16, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR

The 56 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Jul 22, 2026	RA CAPITAL MANAGEMENT, L.P.Director	Buy	47,250	$29.77	$1.4M	Form 4
Jul 21, 2026	RA CAPITAL MANAGEMENT, L.P.Director	Buy	65,923	$29.25	$1.9M	Form 4
Jul 20, 2026	RA CAPITAL MANAGEMENT, L.P.Director	Buy	131,420	$27.28	$3.6M	Form 4
Jun 15, 2026	SEBULSKY ALANDirector	Buy	9,065	$26.49	$240.2K	Form 4
Jun 12, 2026	SEBULSKY ALANDirector	Buy	8,435	$27.67	$233.4K	Form 4
Jun 11, 2026	RA Capital Nexus Fund III, L.P.Director	Buy	21,188,750	$20.00	$423.8M	Form 4
Jun 11, 2026	Soleus Capital Group, LLC10% owner	Buy	500,000	$20.00	$10.0M	Form 4
Jun 11, 2026	SEBULSKY ALANDirector	Buy	12,500	$20.00	$250.0K	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

ARCH Venture Fund XII, L.P.SCHEDULE 13G, 1 filing Aug 14, 2026²⁴
FMR LLCSCHEDULE 13G, 1 filing Aug 6, 2026²⁵
RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13D, 1 filing Jun 18, 2026²⁶

Money raised

Private offerings the company reported to the SEC on Form D.

Nov 17, 2022Raised $178 million in a private offering of equity Form D: 24 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 78. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Ra Capital Management, L.P.	28,933,371	$791.9M	6.9%	New
Fmr LLC	10,292,735	$281.7M	0.0%	New
ARCH Venture Management, LLC	6,412,780	$175.5M	16.0%	New
venBio Partners LLC	5,266,697	$144.1M	27.8%	New
Alphabet Inc.	4,919,498	$134.6M	0.1%	New
Nextech Invest Ltd.	4,663,176	$127.6M	6.1%	New
Cormorant Asset Management, LP	4,615,612	$126.3M	6.5%	New
Regeneron Pharmaceuticals, Inc.	4,166,666	$114.0M	64.4%	New
Siren, L.L.C.	2,992,259	$81.9M	1.7%	New
Farallon Capital Management, L.l.c.	2,368,200	$64.8M	0.4%	New
Jupiter Topco LLC	2,296,547	$62.7M	0.0%	New
Frazier Life Sciences Management, L.P.	1,920,805	$52.6M	1.1%	New
Deerfield Management Company, L.P.	1,880,704	$51.5M	0.6%	New
General Catalyst Group Management, LLC	1,600,937	$43.8M	23.2%	New
General Atlantic, L.P.	1,538,461	$42.1M	1.4%	New
Soleus Capital Management, L.P.	1,465,070	$40.1M	1.4%	New
Vanguard Portfolio Management LLC	1,302,479	$35.6M	0.0%	New
Vanguard Capital Management LLC	1,156,962	$31.7M	0.0%	New
Jpmorgan Chase & Co	1,042,772	$30.4M	0.0%	New
Foresite Capital Management VI LLC	999,044	$27.3M	4.3%	New
Catalio Capital Management, LP	824,043	$22.6M	4.2%	New
Alliancebernstein L.P.	810,279	$22.2M	0.0%	New
Casdin Capital, LLC	645,690	$17.7M	0.9%	New
Venrock Adviser, LLC	625,000	$17.1M	0.5%	New
Rock Springs Capital Management LP	578,028	$15.8M	0.8%	New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Parabilis Medicines, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARParabilis Medicines, Inc.¹
CIK0001657677
Employer ID (EIN)47-4505725¹
Filer status<br>emerging growth company¹
Incorporated inDelaware¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business address30 Acorn Park Drive, 6Th Floor, Cambridge, MA 02140¹
Phone617-945-9510¹
On EDGAR sinceNov 13, 2015¹
Filings62 in all: 3 (17), 4 (17), 8-K (5), D (5), S-1/A (3), D/A (2), SCHEDULE 13G (2), 10-Q (1)¹
All 18 form types
424B4 (1), 8-A12B (1), CERT (1), DRS (1), EFFECT (1), FWP (1), S-1 (1), S-1MEF (1), S-8 (1), SCHEDULE 13D (1)
Latest filingsQuarterly report (10-Q) Aug 13, 2026
Latest 8-K (8-K) Sep 15, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARParabilis Medicines, Inc. filings on SEC EDGAR
2
SEC EDGARParabilis Medicines, Inc. filings on SEC EDGAR
3
SEC EDGARMathai Mammen, Chief executive officer
4
SEC EDGARThomas Rodolpho Kotarakos, Chief financial officer
5
SEC EDGARHelen Huei-In Ho, Officer
6
SEC EDGARMohammed Fawzi Benzaghou, Chief Medical Officer
7
SEC EDGARRohin Mhatre, Officer
8
SEC EDGARAlan Sebulsky, Board member
9
SEC EDGARAlexis Borisy, Board member
10
SEC EDGARBarbara Weber, Board member
11
SEC EDGAREdward M. Fitzgerald, Board member
12
SEC EDGARJake Simson, Board member
13
SEC EDGARKrishna Yeshwant, Board member
14
SEC EDGARPeter Kolchinsky, Board member
15
SEC EDGARCraig Tendler, Board member
16
SEC EDGARTeresa Jurgensen, General counsel
17
SEC EDGARParabilis Medicines, Inc. Form D naming Gregory L. Verdine
18
SEC EDGARRegulation FD disclosure
19
SEC EDGARExecutive or director change
20
SEC EDGARExecutive or director change; Regulation FD disclosure
21
SEC EDGARResults of operations; Regulation FD disclosure
22
SEC EDGAREntered a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed
23
NasdaqNasdaq calendar
24
SEC EDGARARCH Venture Fund XII, L.P. SCHEDULE 13G on Parabilis Medicines, Inc.
25
SEC EDGARFMR LLC SCHEDULE 13G on Parabilis Medicines, Inc.
26
SEC EDGARRA CAPITAL MANAGEMENT, L.P. SCHEDULE 13D on Parabilis Medicines, Inc.